Switch Language
Alt tag

See Also

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Which Anticoagulant?

The information below is based on European or United Kingdom Summaries of Product Characteristics – approved uses and recommendations for drugs vary by region/country

This table is intended as a quick reference guide only and is not an exhaustive list; refer to local prescribing information for full drug information and use clinical judgement before prescribing

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

When to use a reduced NOAC dose
Patients receiving anticoagulation with a NOAC should receive a reduced dose in certain clinical situations
© Bayer AG, 2017 | Approval number: PP-XAR-ALL-1742-1


The information in this table is taken from the respective Summary of Product Characteristics for the therapies shown, available at the links provided in the table.


Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

Sign up now!